China Artificial Intelligence Drug Research Firm QuantumPharm XtalPi to IPO in Hong Kong on 13th June 2024, Target to Raise $144 Million, First Hong Kong Exchange IPO under Chapter 18C Allowing IPO for Pre-Revenue Technology Firms with at Least HKD 10 Billion Market Value Equivalent to $1.2 Billion, Key Investors Include Tencent, HongShan, China Life Insurance, SoftBank & Google, IPO Cornerstone Investor Includes Chairman of Henderson Land Development Peter Lee Ka-kit Investment Holding Group Successful Lotus, QuantumPharm XtalPi Founded by 3 MIT-Trained Scientists Chairman Dr Wen Shuhao, CEO Dr Ma Jian & Chief Innnovation Officer Dr Lai Liping
7th June 2024 | Hong Kong
China artificial intelligence (AI) drug research firm QuantumPharm (XtalPi) will IPO in Hong Kong (HKEX) on 13th June 2024, targeting to raise $144 million in the IPO. QuantumPharm XtalPi is the first Hong Kong Exchange IPO under the new Chapter 18C regime, allowing IPO for pre-revenue technology firms with at least HKD 10 billion market value ($1.2 billion). QuantumPharm (XtalPi) key investors include Tencent, HongShan, China Life Insurance, SoftBank & Google. QuantumPharm (XtalPi) IPO cornerstone investor includes Chairman of Henderson Land Development Peter Lee Ka-kit, via his investment holding group Successful Lotus. QuantumPharm (XtalPi) is founded by 3 MIT-trained (Massachusetts Institute of Technology) scientists Chairman Dr Wen Shuhao, CEO Dr Ma Jian and Chief Innnovation Officer Dr Lai Liping.
“ China Artificial Intelligence Drug Research Firm QuantumPharm XtalPi to IPO in Hong Kong on 13th June 2024, Target to Raise $144 Million, First Hong Kong Exchange IPO under Chapter 18C Allowing IPO for Pre-Revenue Technology Firms with at Least HKD 10 Billion Market Value Equivalent to $1.2 Billion, Key Investors Include Tencent, HongShan, China Life Insurance, SoftBank & Google, IPO Cornerstone Investor Includes Chairman of Henderson Land Development Peter Lee Ka-kit Investment Holding Group Successful Lotus, QuantumPharm XtalPi Founded by 3 MIT-Trained Scientists Chairman Dr Wen Shuhao, CEO Dr Ma Jian & Chief Innnovation Officer Dr Lai Liping “
China Artificial Intelligence Drug Research Firm QuantumPharm XtalPi to IPO in Hong Kong on 13th June 2024, Target to Raise $144 Million, First Hong Kong Exchange IPO under Chapter 18C Allowing IPO for Pre-Revenue Technology Firms with at Least HKD 10 Billion Market Value Equivalent to $1.2 Billion, Key Investors Include Tencent, HongShan, China Life Insurance, SoftBank & Google, IPO Cornerstone Investor Includes Chairman of Henderson Land Development Peter Lee Ka-kit Investment Holding Group Successful Lotus, QuantumPharm XtalPi Founded by 3 MIT-Trained Scientists Chairman Dr Wen Shuhao, CEO Dr Ma Jian & Chief Innnovation Officer Dr Lai Liping
Sign Up / Register
Caproasia Users
- Manage $20 million to $3 billion of assets
- Invest $3 million to $300 million
- Advise institutions, billionaires, UHNWs & HNWs
Caproasia Platforms | 11,000 Investors & Advisors
- Caproasia.com
- Caproasia Access
- Caproasia Events
- The Financial Centre | Find Services
- Membership
- Family Office Circle
- Professional Investor Circle
- Investor Relations Network
Monthly Roundtable & Networking
Family Office Programs
The 2024 Investment Day
- March 2024 - Hong Kong
- March 2024 - Singapore
- July 2024 - Hong Kong
- July 2024 - Singapore
- Sept 2024 - Hong Kong
- Sept 2024 - Singapore
- Oct 2024 - Hong Kong
- Nov 2024 - Singapore
- Visit: The Investment Day | Register: Click here
Caproasia Summits
- The Institutional Investor Summit
- The Investment / Alternatives Summit
- The Private Wealth Summit
- The Family Office Summit
- The CEO & Entrepreneur Summit
- The Capital Markets Summit
- The ESG / Sustainable Investment Summit